A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT01120561. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, open-label, single-arm, expanded access study designed to provide T-DM1 to patients with HER2-positive locally advanced or metastatic breast cancer and to evaluate the safety and efficacy of T-DM1 administered by intravenous (IV) infusion.
Study identification
- NCT ID
- NCT01120561
- Recruitment status
- No Longer Available
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2010 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Feb 15, 2017
Started 2010
United States locations
- U.S. sites
- 15
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site | Highland | California | 92346 | — |
| Investigational Site | Stockton | California | 95204 | — |
| Investigational Site | Denver | Colorado | 80220 | — |
| Investigational Site | Plantation | Florida | 33324 | — |
| Investigational Site | Lafayette | Indiana | 47905 | — |
| Investigational Site | Cedar Rapids | Iowa | 52403 | — |
| Investigational Site | Scarborough | Maine | 04074 | — |
| Investigational Site | Baltimore | Maryland | 21231 | — |
| Investigational Site | Detroit | Michigan | 48201 | — |
| Investigational Site | Clarkson Valley | Missouri | 63011 | — |
| Investigational Site | Farmington | New Mexico | 87401 | — |
| Investigational Site | Charlotte | North Carolina | 28203 | — |
| Investigational Site | Charleston | South Carolina | 29403 | — |
| Investigational Site | Fairfax | Virginia | 22031 | — |
| Investigational Site | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01120561, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 15, 2017 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01120561 live on ClinicalTrials.gov.